What class of medication are dasatinib and asciminib?

Medication Class of Dasatinib and Asciminib

Both dasatinib and asciminib are tyrosine kinase inhibitors (TKIs), with dasatinib classified as a second-generation TKI and asciminib as a novel allosteric kinase inhibitor (ABL001). 1

Dasatinib Classification and Mechanism

Dasatinib is a second-generation, multi-targeted tyrosine kinase inhibitor that differs fundamentally from first-generation agents like imatinib in both potency and target spectrum. 1

Primary Targets

• BCR-ABL kinase inhibition: Dasatinib demonstrates 325-fold greater potency against wild-type BCR-ABL compared to imatinib in vitro. 1
• SRC family kinase inhibition: Unlike imatinib, dasatinib potently inhibits SRC family kinases (SRC, LCK, HCK, YES, FYN, FGR, BLK, LYN, FRK), which are implicated in alternative signaling pathways that mediate imatinib resistance. 1, 2, 3
• Additional kinase targets: Dasatinib also inhibits c-KIT, PDGFR-α and -β, ephrin receptor kinases, and TEC kinases. 2, 3

Clinical Applications

• Approved indications: Dasatinib is FDA-approved for chronic myeloid leukemia (CML) in all phases, including pediatric patients, and for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) resistant or intolerant to prior therapy. 1, 3
• Mutation coverage: Dasatinib maintains activity against most imatinib-resistant ABL kinase domain mutations, with notable exceptions being T315I, V299L, and F317L mutations. 1

Asciminib Classification and Mechanism

Asciminib (ABL001) represents a novel class of allosteric kinase inhibitor that functions through a fundamentally different mechanism than ATP-competitive TKIs like dasatinib. 1

Unique Mechanism

• Allosteric inhibition: Unlike dasatinib and other conventional TKIs that compete with ATP at the kinase active site, asciminib binds to the myristoyl pocket (STAMP—Specifically Targeting the ABL Myristoyl Pocket), inducing an inactive kinase conformation. 1
• Synergistic potential: This distinct mechanism allows asciminib to act synergistically with available therapeutic modalities used in Ph+ ALL. 1

Clinical Context

• Emerging role: Asciminib is of particular interest in Ph+ ALL due to its favorable toxicity profile and ability to work through a mechanism distinct from conventional TKIs. 1
• Resistance considerations: The allosteric mechanism may provide activity in cases where ATP-competitive TKIs have failed, though optimal positioning in treatment algorithms remains under investigation. 1

Key Distinctions Between Drug Classes

Generation and Potency Hierarchy

• First-generation (imatinib): Standard BCR-ABL inhibitor with limited activity against resistant mutations. 1
• Second-generation (dasatinib, nilotinib, bosutinib): Enhanced potency (dasatinib is 350 times more potent than imatinib in vitro) and broader mutation coverage. 1
• Third-generation (ponatinib): Active against T315I mutation, which confers resistance to all second-generation TKIs. 1
• Allosteric inhibitor (asciminib): Novel mechanism targeting myristoyl pocket rather than ATP-binding site. 1

Clinical Implications of Dasatinib's Multi-Kinase Activity

• Blood-brain barrier penetration: Dasatinib crosses the blood-brain barrier more effectively than imatinib, providing superior CNS coverage in Ph+ ALL. 1
• Immune modulation: Dasatinib's inhibition of SRC family kinases, particularly LCK, suppresses T-cell function at clinically relevant concentrations, which may contribute to large granular lymphocyte expansion observed during therapy. 4, 5

Important Clinical Caveats

Common pitfall: Assuming all TKIs are interchangeable—they are not. Dasatinib's multi-kinase inhibition profile creates unique toxicities (pleural effusion in 28-33% of patients, pulmonary arterial hypertension in 5%) that do not occur with more selective agents. 1, 6

Mutation-specific selection: When BCR-ABL mutations develop, TKI selection must be guided by the specific mutation detected, as each agent has distinct resistance profiles. 1